Enlivex Therapeutics Ltd (ENLV)

Currency in USD
1.170
+0.030(+2.63%)
Real-time Data·
ENLV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ENLV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1701.170
52 wk Range
0.8101.760
Key Statistics
Prev. Close
1.142
Open
1.17
Day's Range
1.17-1.17
52 wk Range
0.81-1.76
Volume
5.09K
Average Volume (3m)
81.5K
1-Year Change
-19.58%
Book Value / Share
0.87
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENLV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.000
Upside
+754.70%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Enlivex Therapeutics Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Enlivex Therapeutics Ltd Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

Compare ENLV to Peers and Sector

Metrics to compare
ENLV
Peers
Sector
Relationship
P/E Ratio
−1.9x−3.8x−0.5x
PEG Ratio
−0.04−0.030.00
Price/Book
1.3x2.5x2.6x
Price / LTM Sales
-11.0x3.2x
Upside (Analyst Target)
-437.5%40.5%
Fair Value Upside
Unlock5.7%4.4%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.000
(+754.70% Upside)

Earnings

Latest Release
May 23, 2025
EPS / Forecast
-0.1535 / -0.16
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ENLV Income Statement

People Also Watch

53,680
NICE
+0.51%
31,970
RMLI
-0.22%
5,500
TEVA
-0.99%
1,279.0
ELAL
0.00%
70,500
DLEKG
-3.36%

FAQ

What Stock Exchange Does Enlivex Therapeutics Ltd Trade On?

Enlivex Therapeutics Ltd is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Enlivex Therapeutics Ltd?

The stock symbol for Enlivex Therapeutics Ltd is "ENLV."

What Is the Enlivex Therapeutics Ltd Market Cap?

As of today, Enlivex Therapeutics Ltd market cap is 27.71M.

What Is Enlivex Therapeutics Ltd's Earnings Per Share (TTM)?

The Enlivex Therapeutics Ltd EPS (TTM) is -0.66.

When Is the Next Enlivex Therapeutics Ltd Earnings Date?

Enlivex Therapeutics Ltd will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is ENLV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Enlivex Therapeutics Ltd Stock Split?

Enlivex Therapeutics Ltd has split 2 times.

How Many Employees Does Enlivex Therapeutics Ltd Have?

Enlivex Therapeutics Ltd has 0 employees.

What is the current trading status of Enlivex Therapeutics Ltd (ENLV)?

As of 25 Jul 2025, Enlivex Therapeutics Ltd (ENLV) is trading at a price of 1.17, with a previous close of 1.14. The stock has fluctuated within a day range of 1.17 to 1.17, while its 52-week range spans from 0.81 to 1.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.